The NMPA has granted BTD for B7-H3-targeted ADC HS-20093 for castration-resistant prostate cancer

Alphamab Oncology announces IND application for TROP2/HER3 bispecific ADC JSKN016SC officially accepted by CDE

Taiho Pharmaceutical and Araris Biotech AG advance ADC ARC-02 into phase 1 clinical development

SYS6051 obtains clinical trial approval in the U.S.

Novartis withdraws EMA application for adding new indication for Pluvicto

Tacalyx secures €11 million to advance lead TACA-targeting ADC programme toward the clinic